Reportlinker Adds World Biological Drugs Market 2011-2021

NEW YORK, April 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Biological Drugs Market 2011-2021

http://www.reportlinker.com/p0470101/World-Biological-Drugs-Market-2011-2021.html

Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now.

What revenues will biopharmaceutical markets achieve from 2011 to 2021? What gains can leading companies achieve? What sales trends will national markets - developed and developing - show?

Our study answers those questions and many others for biological drugs. By ordering now, you can stay ahead. We aim to save you time and aid your decisions.

We analyse sales of biologics - such as monoclonal antibodies, insulins, erythropoietins and interferons - by class and product. What is the next stage of the biotech revolution in pharma? Our report shows you where the biopharma industry is heading. 

The biological drug market is growing faster than the pharmaceutical market overall. Is biotechnological revenue growth sustainable? Our report shows you prospects there.

Our new report also provides an analysis of the biosimilars industry. You will see what will influence the biopharmaceutical industry from 2011 - technologies, policies and competition. 

Our interviews in the biopharma field provide broad and deep perspectives on the challenges facing the industry and market this decade. You will see how.

You can assess the pharma biotechnology industry's strengths, weaknesses, trends and prospects from 2011 onwards. 

Here, you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.

Analysis and expert opinion to help your work - so you won't be left behind

Our new report gives you revenue forecasts, growth rates, market share analysis, SWOT analysis, an R&D review and expert opinion. We include 97 tables and charts and four interviews (shown in the accompanying lists).

World Biological Drugs Market 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

• You will receive hard data for the biological drug industry - especially our revenue forecasts to 2021

• You will discover sales trends for the overall market and its main components from 2009 to 2021 - seeing where commercial growth will occur

• You will see the revenue prospects for 20 leading products from 2011 to 2021, with discussions of market potential and competition

• You will find revenue prospects for leading national markets from 2011 to 2021 (US, Japan, UK, Germany, France, Spain, Italy, China and India)

• You will learn how the industry can change and adapt from 2011 to 2021, including prospects for biosimilars (follow-on biologics)

• You will assess leading companies in pharma biotechnology, discovering their activities and outlook

• You will investigate competition and opportunities influencing the biologicals industry from 2011 onwards

• You will see what will stimulate and restrain the industry and market from 2011 onwards

• You will review product development, assessing the potential of R&D

• You will analyse opportunities for established companies and those seeking to enter the biologics market

• You will view expert opinion from our survey, including full interview transcripts.

That combination of quantitative and qualitative market analysis sets our report apart. We give you original market predictions, found only in our work.

You can order our new report, receiving the market information you need

Our report can benefit everybody interested in pharmaceutical biotechnology. You will see where the industry is heading, assessing the opportunities, needs and challenges.

You will find answers and trends here. We aim to save you time and aid your decisions. Please order our report now, making sure you don't miss out. 

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs

Table of Contents

1. Executive Summary

1.1 Biological Drugs Market Review

1.2 Contents of This Report

1.3 Research and Analysis Methods

2. Overview of the Biological Drugs Market 2011-2021

2.1 The Biological Drugs Market Was Worth over $100bn in 2010

2.2 Market Forecast 2011-2021

2.3 Biological Drugs versus Small Molecules

2.4 Creating Biological Drugs

2.5 Defining the Biotechnology Space

2.6 What is a Biopharmaceutical?

2.7 Vaccines

3. Monoclonal Antibodies Market 2011-2021

3.1 Monoclonal Antibodies in 2009

3.2 The Science of Antibodies

3.3 Murine, Chimeric, Humanised and Fully-Human MAbs

3.4 Prospects for the Monoclonal Antibodies Market

3.5 Top Products in the MAbs Market

3.5.1 Remicade (Johnson & Johnson) 2011-2021

3.5.2 Avastin (Roche) 2011-2021

3.5.3 Rituxan (Roche) 2011-2021

3.5.4 Humira (Abbott) 2011-2021

3.5.5 Herceptin (Roche) 2011-2021

3.5.6 Lucentis (Roche) 2011-2021

3.5.7 Erbitux (Eli Lilly) 2011-2021

3.5.8 Synagis (AstraZeneca) 2011-2021

3.5.9 Tysabri (Biogen Idec) 2011-2021

3.5.10 Xolair (Roche) 2011-2021

4. Therapeutic Proteins Market 2011-2021

4.1 Overall Prospects for Therapeutic Proteins Sector

4.2 Insulin and Insulin Analogues

4.3 Erythropoietins

4.4 Interferons

4.5 Granular-Colony Stimulating Factors (G-CSF)

4.6 Recombinant Coagulation Factors

4.7 Top Products in the Therapeutic Proteins Market

4.7.1 Enbrel (Amgen) 2011-2021

4.7.2 Epogen (Amgen) 2011-2021

4.7.3 Lantus (Sanofi-Aventis) 2011-2021

4.7.4 Neulasta (Amgen) 2011-2021

4.7.5 Aranesp (Amgen) 2011-2021

4.7.6 Avonex (Biogen Idec) 2011-2021

4.7.7 Rebif (Merck Serono) 2011-2021

4.7.8 Advate (Baxter Healthcare) 2011-2021

4.7.9 Humalog (Eli Lilly) 2011-2021

4.7.10 Novorapid (Novo Nordisk) 2011-2021

5. Biosimilars Market 2011-2021

5.1 Forecast for Biosimilars Market, 2011-2021

5.2 Overview of the Biosimilars Market in 2011

5.3 Biosimilar Monoclonal Antibodies

5.4 Biosimilar Insulins

5.5 Biosimilar Erythropoietins

5.6 Biosimilar Interferons

5.7 Biosimilar G-CSF

6. R&D Pipelines for Biological Drugs

6.1 MAbs

6.2 Dalotuzumab (Merck & Co)

6.3 MAb, CCR4 (Amgen)

6.4 MAb, VEGFR-2 (UCB)

6.5 Ramucirumab (Eli Lilly)

6.6 Necitumumab (Eli Lilly)

6.7 Ipilimumab (Bristol-Myers Squibb)

6.8 Tanezumab (Roche)

6.9 Trastuzumab Emtansine (Roche)

6.10 Numax (AstraZeneca)

6.11 Benlysta (Human Genome Sciences/ GSK)

6.12 Ocrelizumab (Roche/ Biogen Idec)

6.13 Denosumab (Amgen)

6.14 Bapineuzumab (Pfizer/ Johnson & Johnson)

6.15 Solanezumab (Eli Lilly)

6.16 Asthma MAb (BioWa)

6.17 Rabies MAb (Crucell/ Merck & Co.)

6.18 Therapeutic Proteins

6.19 Recombinant Human Factor XIII (Novo Nordisk)

6.20 Juvista (Shire)

6.21 Belatacept (Bristol-Myers Squibb)

7. Leading Companies in the Biological Drugs Market

7.1 Roche Controls Nearly a Quarter of the Biological Drugs Market

7.1.1 Roche

7.1.2 Amgen

7.1.3 Johnson & Johnson

7.1.4 Novo Nordisk

7.1.5 Abbott

7.2 Biopharmaceutical M&A

7.2.1 Mega-Mergers

7.2.2 Smaller Acquisitions

7.3 Major Pharma's Emphasis on Biological Drugs

7.3.1 Pfizer

7.3.2 AstraZeneca

7.3.3 Merck & Co.

7.3.4 Novartis

7.3.5 Sanofi-Aventis

7.3.6 Eli Lilly

7.3.7 GlaxoSmithKline

7.3.8 Teva

8. Leading Countries in the Biological Drugs Market

8.1 Leading Biologic Drug National Markets in 2009

8.2 Forecast for National Markets 2011-2021

8.3 The US

8.3.1 The US: Market Forecast 2011-2021

8.4 Europe

8.4.1 Europe: Market Outlook 2011-2021

8.4.2 France: Market Forecast 2011-2021

8.4.3 Germany: Market Forecast 2011-2021

8.4.4 UK: Market Forecast 2011-2021

8.4.5 Italy: Market Forecast 2011-2021

8.4.6 Spain: Market Forecast 2011-2021

8.5 Japan

8.5.1 Japan: Market Forecast 2011-2021

8.6 China

8.6.1 China: Market Forecast 2011-2021

8.7 India

8.7.1 India: Market Forecast 2011-2021

9. Expert Opinion

9.1 Interview with Ronald A. Rader, President, Biotechnology Information Institute

9.1.1 On Defining 'Biopharmaceutical'

9.1.2 On the Future of Biological Drugs

9.1.3 On Lack of Information Resources in the Pharma Industry

9.1.4 On the Regulatory Uncertainty Surrounding Biopharmaceuticals and Biosimilars

9.1.5 On the Potential and the Problems of Biosimilars

9.2 Interview with Dr Janice Reichert, Editor-in-Chief, MAbs

9.2.1 On the Reasons for the Ascendancy of MAbs

9.2.2 On the Current Indications for MAbs

9.2.3 On Antibody-Drug Conjugates and Bispecifics

9.2.4 On Non-Human Antibodies and Alternative Scaffolds

9.2.5 On the Prospects for Biosimilar Antibodies

9.3 Interview with Steven A. Grossman, President, HPS Group, LLC

9.3.1 On the US Biosimilar Industry in the Next Decade

9.3.2 On Different Pathways to Biosimilar Approval

9.3.3 On the Legislation's Effect on Innovative Biological Drugs

9.4 Interview with Dr James DeGiulio, Expert on Patent Applications and Biotechnology Litigation

9.4.1 On the US Biosimilars Pathway

9.4.2 On the Comparison between US and European Biosimilar Markets

9.4.3 On the Challenges for Biosimilars

9.4.4 On the Regulatory Challenges for Innovative Biopharmaceuticals

10. SWOT Analysis of the Biological Drugs Market and Conclusions

10.1 Strengths

10.1.1 The Biological Drugs Market is Well-Established

10.1.2 Biological Products Bring High Revenues for the Industry

10.1.3 Biopharmaceuticals Target Important Therapeutic Areas

10.2 Weaknesses

10.2.1 Biological Drugs Are Costly

10.2.2 The Biologicals Industry is Insufficiently Dynamic?

10.2.3 The Biosimilar Industry - How Will it Affect the Biologics Industry?

10.3 Opportunities

10.3.1 Biosimilars are a Major Growth Opportunity

10.3.2 The Biosimilars Market is Open

10.3.3 Opportunities Remain in the Patented Biopharmaceutical Sector

10.4 Threats

10.4.1 Cost-Cutting Measures May Endanger Biopharmaceutical Growth

10.4.2 There are Outstanding Health Concerns with Some Biological Products

10.4.3 Clearer Regulatory Policy Would Benefit the Biologics Industry

10.5 Concluding Remarks

List of Tables

Table 2.1 Biological Drugs Market, Revenues ($bn), Shares of Overall Pharmaceutical Market, 2009

Table 2.2 Sectors of the Biological Drugs Market, Revenues ($bn), Market Shares (%) 2009

Table 2.3 Global Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 2.4 Global Biological Drugs Market by Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 2.5 Strengths and Weaknesses of Biological Drugs Compared with Small-Molecule Drugs

Table 3.1 Monoclonal Antibodies, Revenues ($bn), 2009

Table 3.2 Monoclonal Antibodies Market by Indication, Revenues ($bn), Market Shares (%), 2009

Table 3.3 Monoclonal Antibodies Market, Revenues ($bn), Annual Growth (%), CAGR (%), Shares of Biological Drug Market (%), 2009-2021

Table 3.4 Remicade Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.5 Avastin Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.6 Rituxan Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.7 Humira Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.8 Herceptin Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.9 Lucentis Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.10 Erbitux Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.11 Synagis Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.12 Tysabri Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 3.13 Xolair Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.1 Therapeutic Proteins Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.2 Insulins Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.3 Erythropoietins Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.4 Interferons Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.5 G-CSF Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.6 Recombinant Coagulation Factors Class, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.7 Enbrel, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.8 Epogen, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.9 Lantus, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.10 Neulasta, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.11 Aranesp, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.12 Avonex, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.13 Rebif, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.14 Advate, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.15 Humalog, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 4.16 NovoRapid, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 5.1 Biosimilars Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 7.1 Top Companies in the Biological Drugs Market, Revenues ($bn), Market Shares (%), Lead Products, 2009

Table 8.1 Top Countries in the Biological Drugs Market, Revenues ($bn), Market Shares (%)

Table 8.2 Regions in the Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021

Table 8.3 US: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.4 European Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.5 France: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.6 Germany: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.7 UK: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.8 Spain: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.9 Italy: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.10 Japan: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.11 China: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 8.12 India: Biological Drugs Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 

Table 10.1 SWOT Analysis of the Biological Drugs Market, 2011

List of Figures

Figure 2.1 Biological and Non-Biological Drugs Markets, Revenues ($bn), 2009

Figure 2.2 Sectors of the Biological Drugs Industry, Market Shares, 2009

Figure 2.3 Global Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 2.4 Sectors of the Biological Drugs Industry, Market Shares, 2021

Figure 2.5 Global Biological Drugs Market by Sector, Revenues ($bn), 2009-2021

Figure 3.1 Monoclonal Antibodies, Revenues ($bn), Other Biological Drugs Market Revenues ($bn), 2009

Figure 3.2 Monoclonal Antibodies, Revenues ($bn), Total Pharmaceutical Market Revenues ($bn), 2009

Figure 3.3 Monoclonal Antibodies, Indications, Revenues ($bn), 2009

Figure 3.4 Monoclonal Antibodies, Market Revenues ($bn), 2009-2021

Figure 3.5 Remicade Revenues ($bn), 2009-2021

Figure 3.6 Avastin Revenues ($bn), 2009-2021

Figure 3.7 Rituxan Revenues ($bn), 2009-2021

Figure 3.8 Humira Revenues ($bn), 2009-2021

Figure 3.9 Herceptin Revenues ($bn), 2009-2021

Figure 3.10 Lucentis Revenues ($bn), 2009-2021

Figure 3.11 Erbitux Revenues ($bn), 2009-2021

Figure 3.12 Synagis Revenues ($bn), 2009-2021

Figure 3.13 Tysabri Revenues ($bn), 2009-2021

Figure 3.14 Xolair Revenues ($bn), 2009-2021

Figure 4.1 Therapeutic Proteins: Revenues ($bn), 2009-2021

Figure 4.2 Insulins, Revenues ($bn), 2009-2021

Figure 4.3 Erythropoietins, Revenues ($bn), 2009-2021

Figure 4.4 Interferons, Revenues ($bn), 2009-2021

Figure 4.5 G-CSF, Revenues ($bn), 2009-2021

Figure 4.6 Recombinant Coagulation Factors, Revenues ($bn), 2009-2021

Figure 4.7 Enbrel, Revenues ($bn), 2009-2021

Figure 4.8 Epogen, Revenues ($bn), 2009-2021

Figure 4.9 Lantus, Revenues ($bn), 2009-2021

Figure 4.10 Neulasta, Revenues ($bn), 2009-2021

Figure 4.11 Aranesp, Revenues ($bn), 2009-2021

Figure 4.12 Avonex, Revenues ($bn), 2009-2021

Figure 4.13 Rebif, Revenues ($bn), 2009-2021

Figure 4.14 Advate, Revenues ($bn), 2009-2021

Figure 4.15 Humalog, Revenues ($bn), 2009-2021

Figure 4.16 NovoRapid, Revenues ($bn), 2009-2021

Figure 5.1 Biosimilars Sector Revenues ($bn), 2009-2021

Figure 7.1 Top Companies in the Biological Drugs Market, Revenues ($bn), 2009

Figure 8.1 Regions in the Biological Drugs Market, Revenues ($bn), 2009

Figure 8.2 US Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.3 European Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.4 France: Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.5 Germany: Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.6 UK: Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.7 Spain: Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.8 Italy: Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.9 Japan: Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.10 China: Biological Drugs Market, Revenues ($bn), 2009-2021

Figure 8.11 India: Biological Drugs Market, Revenues ($bn), 2009-2021

Companies Listed

Abbott Laboratories

Ablynx

Adnexus

Affibody

Alcon

Alkermes

Alnylam

Amerisource Bergen

Amgen

Arrow

Aspreva Pharmaceuticals

AstraZeneca

Athena Neurosciences

Baxter Healthcare

Bayer Schering Pharma

Becton, Dickinson and Company (BD) 

Beijing Shuanglu

Berlex

Biocon 

Biogen Idec

Biopartners

BioRexis

Biotechnology Information Institute

Bioton

BioWa

Bristol-Myers Squibb

Cambridge Antibody Technology

Celgene

Celltech

Centocor Ortho Biotech

Centyrex

Chugai

Cipla

CJ Corporation

Cougar Biotechnology

Covagen

Crucell Biotechnology

CT Arzneimettel

Daiichi Sankyo

Dainippon Sumitomo

Department of Health and Human Services

Dompé Farmaceutici 

Dong-A

Dr. Reddy's Laboratories

Dyax 

Eisai

Elan

Eli Lilly

European League Against Rheumatism

European Medicines Agency (EMA/EMEA)

Facet Biotech

Feron

Food and Drug Administration (FDA)

Forest Laboratories

Fovea

Fresenius

Genentech

GeneScience

Genesis Pharma

Genetics Institute

GenMab

Getz Pharma

Gilead Sciences

GlaxoSmithKline

GlycoFi

Halozyme

Haptogen

Hexal

Hoechst Marion Roussel

Hospira

HPS Group, LLC

Hualida Biotech

Human Genome Sciences

ImClone Systems

Immunex

Insmed

Intas Biopharmaceuticals

International Nephrology Network

Jiangsu Walvax Biotech Company

Johnson & Johnson

King

Knoll

Kyowa Hakko Kirin Co.

La Jolla Pharmaceuticals

LG Life Sciences

Lonza Biologics 

Lupin Pharma

MAbs 

Medarex

Medicare

Medice

MedImmune

Medixion

Megapharm

Merck & Co.

Merck BioVentures

Merck KGaA

Merck Serono

Micromet

Ministry of Health, Labor and Welfare (MHLW)

Mitsubishi Tanabe Pharma

Molecular Partners

Momenta

National Health Service (NHS)

National Institute for Health and Clinical Excellence (NICE)

Nektar

NICE

Novartis

Novo Nordisk

OPKO Health

Ortho Pharmaceutical Corporation

Peptech

Pfizer

Pharmacoepia

Pieris

Pierre Fabre

Piramal

Procter & Gamble

Qilu

QLT

Regeneron

Reliance Life Sciences

Rinat

Roche

Sandoz

Sanofi-Aventis

Schering-Plough

Seattle Genetics

Shantha Biotechnics

Shire

Sidus

Solvay Pharmaceuticals

State Food and Drug Administration

SurModics

Takeda Pharmaceutical Industries

Tanox Biosystems

Targacept

Teva Pharmaceuticals

Tianjin Medical University Cancer Hospital

Tonghua Dongbao

Transkaryotic Therapies

Tufts Center for the Study of Drug Development

UCB

Vical

Wockhardt

Wyeth (now part of Pfizer) 

Ypsomed

Zenyaky Kogyo

ZymoGenerics

To order this report:

: World Biological Drugs Market 2011-2021

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker